$JAZZJazz Pharmaceuticals plc

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
  The FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancer
  stat · 23h ago
• STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism
  A lab that tussled with regulators over impurities found in widely used medicines has accused U.S. Pharmacopeia of making false and misleading remarks about its methods.
  stat · 23h ago
• STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
  Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
  stat · 1d ago
• 7 companies hiring in North Carolina now
  Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.
  biospace · 2d ago
• STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
  Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide
  stat · 2d ago
• STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
  The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis
  stat · 3d ago
• Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
  Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
  biopharma_dive · 4d ago
• Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
  Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
  biospace · 4d ago
• Jazz bets on epilepsy again by acquiring Actio for $820M upfront
  Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug. The deal further solidifies Jazz…
  endpoints · 4d ago
• STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
  Sanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issues
  stat · 4d ago